

Daniel J Felmlee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1604948/publications.pdf>

Version: 2024-02-01

31
papers

1,393
citations

430754

18
h-index

501076

28
g-index

31
all docs

31
docs citations

31
times ranked

2035
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis C Virus Induces Proteolytic Cleavage of Sterol Regulatory Element Binding Proteins and Stimulates Their Phosphorylation via Oxidative Stress. <i>Journal of Virology</i> , 2007, 81, 8122-8130.	1.5	240
2	A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses. <i>Hepatology</i> , 2016, 63, 35-48.	3.6	131
3	Hepatitis C Virus Entry. <i>Current Topics in Microbiology and Immunology</i> , 2013, 369, 87-112.	0.7	130
4	Hepatitis C Virus, Cholesterol and Lipoproteins – Impact for the Viral Life Cycle and Pathogenesis of Liver Disease. <i>Viruses</i> , 2013, 5, 1292-1324.	1.5	126
5	Reconstitution of the Entire Hepatitis C Virus Life Cycle in Nonhepatic Cells. <i>Journal of Virology</i> , 2012, 86, 11919-11925.	1.5	83
6	Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals. <i>Viruses</i> , 2015, 7, 6716-6729.	1.5	72
7	Intravascular Transfer Contributes to Postprandial Increase in Numbers of Very-Low-Density Hepatitis C Virus Particles. <i>Gastroenterology</i> , 2010, 139, 1774-1783.e6.	0.6	68
8	Syndecan 4 Is Involved in Mediating HCV Entry through Interaction with Lipoviral Particle-Associated Apolipoprotein E. <i>PLoS ONE</i> , 2014, 9, e95550.	1.1	64
9	Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies. <i>Gastroenterology</i> , 2016, 150, 206-217.e4.	0.6	64
10	Hepatitis C Virus Nonstructural Proteins Inhibit Apolipoprotein B100 Secretion. <i>Journal of Biological Chemistry</i> , 2005, 280, 39802-39808.	1.6	59
11	HCV and the hepatic lipid pathway as a potential treatment target. <i>Journal of Hepatology</i> , 2011, 55, 1428-1440.	1.8	54
12	Entry of hepatitis B and C viruses – recent progress and future impact. <i>Current Opinion in Virology</i> , 2014, 4, 58-65.	2.6	43
13	New perspectives for preventing hepatitis C virus liver graft infection. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 735-745.	4.6	41
14	Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: Evidence for an association with interferon sensitivity. <i>Journal of Hepatology</i> , 2012, 57, 32-38.	1.8	35
15	Hepatitis C virus vaccines – Progress and perspectives. <i>Microbial Pathogenesis</i> , 2013, 58, 66-72.	1.3	34
16	PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: Evidence for genotype-specific regulation of lipoprotein metabolism. <i>Journal of Hepatology</i> , 2015, 62, 763-770.	1.8	33
17	Neutralizing Antibodies and Pathogenesis of Hepatitis C Virus Infection. <i>Viruses</i> , 2012, 4, 2016-2030.	1.5	23
18	Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infection. <i>Gut</i> , 2011, 60, 680-687.	6.1	20

#	ARTICLE	IF	CITATIONS
19	Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy – a pilot randomised clinical trial. <i>Liver International</i> , 2014, 34, 737-747.	1.9	12
20	Zooming in on liver zonation. <i>Hepatology</i> , 2018, 67, 784-787.	3.6	11
21	Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency. <i>Metabolic Brain Disease</i> , 2014, 29, 625-634.	1.4	9
22	Interferon-lambda polymorphisms and hepatitis C virus clearance revisited. <i>Hepatology</i> , 2013, 58, 439-441.	3.6	8
23	Infection with the hepatitis C virus causes viral genotype-specific differences in cholesterol metabolism and hepatic steatosis. <i>Scientific Reports</i> , 2022, 12, 5562.	1.6	8
24	Cholesterol uptake and hepatitis C virus entry. <i>Journal of Hepatology</i> , 2012, 57, 215-217.	1.8	7
25	Unraveling hepatitis C virus structure. <i>Cell Research</i> , 2014, 24, 385-386.	5.7	6
26	Lipid interactions influence hepatitis C virus susceptibility and resistance to infection. <i>Clinical Liver Disease</i> , 2017, 10, 17-20.	1.0	6
27	Hepatitis C virus co-opts innate immunity component for lipid droplet formation. <i>Journal of Hepatology</i> , 2013, 59, 1118-1120.	1.8	5
28	Low density Hepatitis C virus particles (lipoviral particles) associate with insulin resistance in genotype 1 infection. <i>Atherosclerosis</i> , 2010, 213, e4.	0.4	1
29	Modeling the antiviral activity of ribavirin against hepatitis C virus in cell culture. <i>Hepatology</i> , 2013, 58, 1203-1206.	3.6	0
30	New tool for the study of hepatitis C virus genotype 3 and its associated liver disease biology. <i>Hepatology</i> , 2014, 60, 1806-1808.	3.6	0
31	Investigation of microbiome metabolites and mitochondrial function in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 73, S240.	1.8	0